

GANCICLOVIR

Trade Name	Cymevene® Roche
Class	Antiviral
Mechanism of Action	Inhibits viral DNA synthesis by competitively preventing binding of deoxyguanosine triphosphate to DNA polymerase.
Indications Individual ID approval required for full treatment course	Treatment of symptomatic cytomegalovirus (CMV) infection
Contraindications	Hypersensitivity to ganciclovir or valganciclovir. Neutrophil count <0.5 Platelet count < 25 Haemoglobin < 80 g/L
Supplied As	500mg powder for IV infusion Pharmacy will organise sterile reconstitution by Baxter on an individual basis. The product will be presented in an oral syringe as a 5mg/mL solution in a volume to give the required dose.
Dilution	Not required
Dosage	IV: 6mg/kg/dose Neofax recommend reducing dose by 50% if neutropenic (<500 cells/mm ³)
Interval	12 hourly for 6 weeks
Administration	Infuse over 1 hour via a central venous line when possible (pH= 11 which makes the solution irritant to veins) Peripheral infusion can be used in urgent situations Do not administer subcutaneously or intramuscularly
Compatible With	Solutions: Sodium chloride 0.9%, glucose 5%, lactated ringers Y –site: Amphotericin (liposomal), atenolol, atropine, calcium chloride, calcium gluconate, dexamethasone, dexmedetomidine, enalaprilat, epoietin, fluconazole, furosemide, heparin, insulin (neutral), labetalol, linezolid, milrinone, pamidronate, pancuronium, pantoprazole, phenobarbitone, potassium chloride, propranolol, ranitidine, remifentanyl, sodium acetate.
Incompatible With	Solutions: Lipid Y-site: adrenaline, amoxicillin, amphotericin (standard), aztreonam, cefepime, cotrimoxazole, dobutamine, dopamine, gentamicin, metronidazole, midazolam, morphine, phenytoin, piperacillin/tazobactam, sodium bicarbonate, vancomycin, vasopressin.

